Opella chief marketing officer Claudine Patel discusses the company’s latest social-first campaign for Aspercreme, which unpacks stigmas around aging.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

What does this Advisor Specialize in? Find a financial advisor who specializes in the area of expertise you require. It's important to find an advisor who can help you approach your personal and ...

In ulcerative colitis, duvakitug led to clinical remission in up to 48% of patients, with placebo-adjusted rates of 27% at the highest dose. In Crohn's disease, duvakitug achieved endoscopic ...

Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 percent controlling stake in Opella to CD&R, following completion of the ...

The development follows Sanofi and Clayton, Dubilier & Rice (CD&R) entering into exclusive negotiations whereby CD&R Group has agreed to acquire a controlling stake in Opella, which holds a 60.4 per ...

Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the share purchase agreement in relation to the sale of a 50% controlling stake in ...

Sanofi’s sale of its $17bn consumer health business Opella just advanced a step closer, after the drugmaker signed a share purchase agreement with buyer Clayton Dubilier & Rice (CD&R).

Sanofi (NASDAQ:SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, its consumer healthcare business, to private equity firm CD&R. The terms of ...

The biggest deal on investors’ radars is an €8.65 billion loan-and-bond package backing Clayton Dubilier & Rice’s buyout of a part of Sanofi SA’s consumer arm, Opella. Still, that’s ...

Bpifrance is expected to participate as a minority shareholder with a c.2% stake in Opella, with Sanofi remaining a significant shareholder. The terms of the transaction remain unchanged from ...